WHY THIS MATTERS
- Nephrotoxicity accounts for 20% of acute kidney injury cases in hospitalized patients
- Drug-induced kidney injury is a leading cause of clinical trial failure and drug withdrawal
- Human kidney models predict nephrotoxicity with 80%+ accuracy vs 50% for animals
- Kidney chips can model renal drug transporters (OAT, OCT) critical for drug clearance
- Enables study of chronic kidney damage impossible in short-term animal studies
EXECUTIVE SUMMARY
Kidney models represent a critical advancement in drug safety testing. The kidney is responsible for filtering blood and eliminating drugs and their metabolites, making it highly vulnerable to toxic injury. Drug-induced nephrotoxicity accounts for 20% of acute kidney injury (AKI) cases in hospitalized patients and is a leading cause of clinical trial failures. Human kidney-on-chip and organoid platforms now enable accurate prediction of nephrotoxicity using functional renal transporters and proximal tubule cells that respond to drugs exactly as human kidneys do.
IN THIS GUIDE
What Are Kidney Models?
Kidney models are in vitro platforms that recreate the structure and function of human kidney tissue for drug testing and disease research. Unlike traditional 2D cell cultures, these advanced models incorporate fluid flow, 3D architecture, and multiple cell types to accurately replicate how the kidney processes drugs and responds to toxic insults.
Microfluidic devices containing proximal tubule epithelial cells cultured under continuous fluid flow. Features functional drug transporters (OAT1, OAT3, OCT2), tight junctions, and polarized cell morphology. Enables real-time monitoring of drug uptake and toxicity markers.
Self-organizing 3D structures derived from iPSCs or adult stem cells that contain multiple nephron cell types including podocytes, proximal tubule cells, loop of Henle cells, and collecting duct cells. Enable disease modeling with patient-specific genetics.
Simplified models focusing on the proximal tubule where 70% of drug-induced nephrotoxicity occurs. Available in multi-well formats (96-well, 384-well) for high-throughput compound screening. Often use immortalized cell lines (RPTEC, HK-2) or primary human cells.
3D bioprinted kidney constructs with controlled architecture and vascularization. Combines multiple cell types in defined spatial arrangements. Emerging technology for complex tissue modeling and potential regenerative medicine applications.
The Nephrotoxicity Challenge
The kidney is uniquely vulnerable to drug-induced injury due to its role in filtering blood and concentrating drugs for excretion. Understanding why nephrotoxicity is so problematic is essential for appreciating the value of advanced kidney models.
WHY THE KIDNEY IS VULNERABLE TO DRUG TOXICITY
- High Blood Flow: The kidneys receive 20-25% of cardiac output despite representing only 0.5% of body weight, exposing renal cells to high drug concentrations
- Drug Concentration: As the kidney concentrates urine, drugs and metabolites can reach concentrations 100-1000x higher than plasma levels in the tubular lumen
- Active Transport: Renal transporters actively uptake drugs into tubular cells, leading to intracellular accumulation and toxicity
- Metabolic Activity: Proximal tubule cells have high metabolic rates and mitochondrial content, making them susceptible to metabolic toxins
- Limited Regeneration: While some renal cell types can regenerate, chronic injury leads to fibrosis and permanent nephron loss
Common Nephrotoxic Drug Classes
Aminoglycoside Antibiotics
Gentamicin, tobramycin, amikacin. Accumulate in proximal tubule cells via megalin-mediated endocytosis. Cause acute tubular necrosis in 10-25% of patients.
Chemotherapy Agents
Cisplatin, methotrexate, ifosfamide. Cisplatin causes nephrotoxicity in 20-30% of patients via OCT2 uptake and mitochondrial damage.
NSAIDs
Ibuprofen, naproxen, celecoxib. Inhibit prostaglandin synthesis, reducing renal blood flow. Cause acute interstitial nephritis and papillary necrosis.
Antivirals
Tenofovir, adefovir, cidofovir. OAT1-mediated uptake leads to proximal tubule toxicity. Fanconi syndrome in severe cases.
Contrast Agents
Iodinated contrast media. Cause contrast-induced nephropathy (CIN) in 2-25% of patients, higher in those with pre-existing kidney disease.
Immunosuppressants
Cyclosporine, tacrolimus. Cause chronic nephrotoxicity through vasoconstriction and tubulointerstitial fibrosis. Limit long-term transplant outcomes.
THE PREDICTION PROBLEM
Animal models poorly predict human nephrotoxicity due to species differences in renal transporters, drug metabolism, and nephron structure. Rats lack OAT3 expression similar to humans, while mouse nephrons differ in architecture from human kidneys. This translational gap means drugs that appear safe in animals can cause severe kidney injury in humans, while potentially safe drugs may be inappropriately terminated based on animal toxicity findings.
Kidney Anatomy and Function
Understanding kidney anatomy is essential for appreciating how kidney models work and which aspects of renal physiology they recreate. The functional unit of the kidney is the nephron, of which each human kidney contains approximately 1 million.
THE NEPHRON: STRUCTURE AND FUNCTION
1. Glomerulus
A tuft of capillaries surrounded by Bowman's capsule where blood filtration begins. Podocytes form the filtration barrier, allowing small molecules to pass while retaining proteins and blood cells. Glomerular filtration rate (GFR) is a key measure of kidney function.
2. Proximal Convoluted Tubule (PCT)
The primary site of drug-induced nephrotoxicity. Reabsorbs 65-70% of filtered sodium, water, glucose, and amino acids. Contains high concentrations of drug transporters (OATs, OCTs) and metabolic enzymes. Brush border membrane increases surface area for transport.
3. Loop of Henle
Creates the concentration gradient that enables urine concentration. Descending limb is permeable to water; ascending limb actively transports sodium. Important for understanding loop diuretic toxicity and electrolyte disorders.
4. Distal Convoluted Tubule (DCT)
Fine-tunes sodium and potassium balance under hormonal control (aldosterone). Contains the sodium-chloride cotransporter (NCC), target of thiazide diuretics.
5. Collecting Duct
Final site of urine concentration under ADH control. Principal cells regulate sodium and potassium; intercalated cells regulate acid-base balance. Target of potassium-sparing diuretics and aquaporin-based drug interactions.
Key Kidney Functions Replicated in Models
Kidney organoids can form glomerular structures with podocytes, though perfusable filtration remains challenging. Used to model glomerular diseases like FSGS.
Kidney chips accurately replicate proximal tubule reabsorption of glucose, amino acids, and drugs. Essential for understanding drug interactions with renal transporters.
Active secretion of drugs via OATs and OCTs is well-replicated in chip models. Critical for predicting drug-drug interactions affecting renal clearance.
Key Drug Transporters in Kidney Models
Renal drug transporters are membrane proteins that actively move drugs across tubular cell membranes. They determine both drug clearance and susceptibility to nephrotoxicity. Advanced kidney models must express functional transporters to accurately predict human responses.
ORGANIC ANION TRANSPORTERS (OATs)
| OAT1 | Basolateral uptake transporter. Mediates entry of anionic drugs (antivirals, NSAIDs, diuretics, antibiotics) into tubular cells. Key determinant of tenofovir, cidofovir, and adefovir nephrotoxicity. Inhibited by probenecid. |
| OAT3 | Basolateral uptake transporter with overlapping but distinct substrate specificity from OAT1. Transports methotrexate, cimetidine, and many antibiotics. Important for drug-drug interactions affecting renal clearance. |
| OAT4 | Apical transporter involved in reabsorption of organic anions. Less characterized but contributes to drug handling in the proximal tubule. |
ORGANIC CATION TRANSPORTERS (OCTs)
| OCT2 | Primary basolateral cation transporter in human kidney. Mediates uptake of metformin, cisplatin, oxaliplatin, and many cationic drugs. OCT2 polymorphisms affect cisplatin nephrotoxicity risk. Critical for diabetes drug (metformin) clearance. |
| MATE1/2 | Apical efflux transporters that work with OCT2 to complete cationic drug secretion. MATE inhibition can increase nephrotoxicity by preventing drug efflux into urine. |
EFFLUX TRANSPORTERS
| MRP2 | Multidrug resistance-associated protein 2. Apical efflux of conjugated metabolites (glucuronides, glutathione conjugates). Protects cells by exporting potentially toxic conjugates into urine. |
| MRP4 | Basolateral and apical efflux transporter for nucleotide analogs and cyclic nucleotides. Involved in tenofovir transport and resistance. |
| P-gp | P-glycoprotein (MDR1/ABCB1). Apical efflux pump for hydrophobic and cationic drugs. Protects against accumulation of digoxin, cyclosporine, and chemotherapy agents in tubular cells. |
TRANSPORTER EXPRESSION IN KIDNEY MODELS
A key advantage of kidney-on-chip technology is the maintenance of functional transporter expression under flow conditions. Static 2D cultures rapidly lose transporter activity, but fluid shear stress in chip systems maintains physiological expression levels of OAT1, OAT3, and OCT2 for weeks. This enables accurate prediction of transporter-mediated nephrotoxicity and drug-drug interactions that are missed by traditional cell culture.
Disease Modeling with Kidney Platforms
Beyond nephrotoxicity testing, kidney models enable study of genetic and acquired kidney diseases using patient-derived cells or genetic engineering approaches.
Kidney organoids derived from PKD patient iPSCs or with CRISPR-edited PKD1/PKD2 mutations spontaneously form cysts, recapitulating the disease phenotype. Used to test cyst-reducing therapies and understand cystogenesis mechanisms. Key model for studying the most common genetic cause of kidney failure.
Kidney chips exposed to high glucose and advanced glycation end products (AGEs) develop hallmarks of diabetic kidney disease including thickened basement membrane, altered transporter function, and inflammatory marker expression. Enables testing of SGLT2 inhibitors and other diabetic nephropathy therapeutics.
Ischemia-reperfusion injury can be modeled by oxygen-glucose deprivation followed by reoxygenation. Cisplatin-induced AKI models enable testing of nephroprotective strategies. Sepsis-associated AKI modeled with endotoxin and inflammatory cytokines.
Kidney organoids with podocyte-specific mutations or patient-derived cells model FSGS pathology. Used to study podocyte injury, proteinuria mechanisms, and test podocyte- protective therapies. Genetic forms (NPHS1, NPHS2 mutations) particularly well-suited.
Kidney organoids support BK polyomavirus infection, enabling study of virus-host interactions and testing antiviral strategies. Critical for transplant nephrology where BKV causes graft loss in 1-10% of kidney transplant recipients.
Kidney chips with fibroblasts and repeated injury can model fibrotic progression characteristic of CKD. TGF-beta stimulation induces fibrotic marker expression. Enables testing of anti-fibrotic therapies for this condition affecting 15% of adults.
Platform Comparison: Kidney Models
Each kidney model platform has distinct strengths and limitations. Selecting the right platform depends on the specific research question, throughput requirements, and biological complexity needed.
| Feature | Kidney-Chip | Kidney Organoids | Proximal Tubule Models | Animal Models |
|---|---|---|---|---|
| Transporter Function | Excellent (OAT1, OAT3, OCT2) | Moderate | Variable | Species-dependent |
| Nephron Complexity | Proximal tubule focus | Multiple segments | Single cell type | Complete nephron |
| Fluid Flow | Yes (physiological) | Limited | No (static) | Yes (in vivo) |
| Throughput | Low-Medium | Medium | High (384-well) | Very Low |
| Culture Duration | Up to 28 days | Months | Days to weeks | Lifetime |
| Patient-Specific | Yes (with iPSCs) | Yes (iPSC-derived) | Limited | No |
| Human Relevance | High | High | Moderate | Low (50% accuracy) |
| Cost per Study | $20K-$50K | $10K-$30K | $5K-$15K | $50K-$200K+ |
| Systemic Effects | No (kidney only) | No (kidney only) | No | Yes |
Note: The optimal approach often combines multiple platforms - high-throughput screening with proximal tubule models, followed by detailed mechanistic studies in kidney chips or organoids, with selective animal studies for systemic effects.
Leading Companies in Kidney Model Development
Emulate, Inc.
Offers the Kidney-Chip as part of their organ-on-chip portfolio. Features human proximal tubule epithelial cells with functional OAT1, OAT3, and OCT2 transporters under physiological flow conditions. Validated for cisplatin and aminoglycoside nephrotoxicity detection. Integrated with their Zoe Culture Module and analysis software.
OrganoPlate Kidney tubule model in 384-well format enables high-throughput nephrotoxicity screening. Features leak-tight tubules with brush border formation and functional transporters. Partner with major pharma including Roche and Janssen for kidney safety assessment.
Developed kidney-on-chip technology focused on renal transporter function. Acquired by Quris-AI in October 2024, integrating kidney chip data with AI-powered toxicity prediction. ParVivo kidney chips validated for OAT1/OAT3 and OCT2-mediated drug transport.
Adult stem cell-derived kidney organoids for disease modeling and drug screening. Patient-derived organoids enable personalized nephrotoxicity prediction. PKD organoid models commercially available for cystic disease research.
PhysioMimix platform includes kidney module that can be connected with liver and other organs for systemic toxicity studies. Enables study of drug metabolite nephrotoxicity following hepatic biotransformation. Multi-organ approach for complex PK/PD studies.